The latest edition of the PD(L)anner looks at clinical, regulatory, and commercial milestones in the field of PD-(L)1 inhibitors since we released our last report in September 2022. A major focus of this issue is combinations of inhibitors of PD-(L)1 and novel immuno-oncology mechanisms.
You can also listen to our podcast that accompanies this edition in which Jacob Plieth talks through some of the highlights with Bertrand Delsuc, publisher of BioTech Radar.
Share
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
The US Healthcare system is a vast, unwieldy beast that requires significant navigation by any company in the healthcare space. Whether you’re a Big Pharma, a small biotech or an ...
Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need ...
Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay ...
The number of cell and gene therapy (C>)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market ...
2023 is a year that many in the pharma market will be happy to see the back of, and the digital health ecosystem is no exception. Some of this can ...
Our focus was on the 2024 Preview, our annual report that looks at the top drugs, companies, potential launches and much more for the year ahead. In the webinar, our ...
